Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
David Hodgson(The University of Texas MD Anderson Cancer Center), Lois B. Travis(Indiana University – Purdue University Indianapolis), Graça M. Dores(United States Food and Drug Administration), Per Hall(Karolinska Institutet), Hans H. Storm(Danish Cancer Society), Sophie D. Fosså(Oslo University Hospital), Eero Pukkala(Tampere University), Magnus Kaijser(Karolinska University Hospital), Charles F. Lynch(University of Iowa), Heikki Joensuu(Orion Corporation (Finland)), Michael Andersson(University of Copenhagen), Ethel S. Gilbert(National Institutes of Health), Frøydis Langmark(Norwegian Cancer Society), Sara J. Schonfeld(National Cancer Institute)
Cited by 348
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland
|New England Journal of Medicine|2000|4.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k